Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Briki

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bionanoscience|March 23, 2026
Dual-Biosensor for Five Drugs Detection in Precision OncologyFrancesca Rodino, Myriam Briki, Thierry Buclin, et al.
Antiviral Therapy|April 15, 2025
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepineMicol Pallanza, Paul Thoueille, Myriam Briki, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2025
Population pharmacokinetics of bictegravir in real-world people with HIVPierre Ekobena, Myriam Briki, Kim Dao, et al.
Pharmaceutics|April 28, 2023
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A PerspectiveMyriam Briki, Pascal André, Yann Thoma, et al.
Therapeutic Drug Monitoring|September 24, 2025
Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current ChallengesSandro Carrara, Nicolas Widmer, Francesca Rodino, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2026
Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokineticsMyriam Briki, Paul Thoueille, Markus Joerger, et al.
Chemotherapy|November 7, 2024
Importance of Sex-Dependent Differences for Dosing Selection and Optimization of Chemotherapeutic DrugsClaire Seydoux, Myriam Briki, Anna D Wagner, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bionanoscience|March 23, 2026
Dual-Biosensor for Five Drugs Detection in Precision OncologyFrancesca Rodino, Myriam Briki, Thierry Buclin, et al.
Antiviral Therapy|April 15, 2025
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepineMicol Pallanza, Paul Thoueille, Myriam Briki, et al.
The Journal of Antimicrobial Chemotherapy|August 13, 2025
Population pharmacokinetics of bictegravir in real-world people with HIVPierre Ekobena, Myriam Briki, Kim Dao, et al.
Pharmaceutics|April 28, 2023
Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A PerspectiveMyriam Briki, Pascal André, Yann Thoma, et al.
Therapeutic Drug Monitoring|September 24, 2025
Therapeutic Drug Monitoring and Point-of-Care Technologies: Opportunities and Current ChallengesSandro Carrara, Nicolas Widmer, Francesca Rodino, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2026
Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokineticsMyriam Briki, Paul Thoueille, Markus Joerger, et al.
Chemotherapy|November 7, 2024
Importance of Sex-Dependent Differences for Dosing Selection and Optimization of Chemotherapeutic DrugsClaire Seydoux, Myriam Briki, Anna D Wagner, et al.
Pageof 1